AA
$3.90
+0.16
(+4.28%)
As of Oct 20, 2026, 5:13 PM EDT
Price history
Aardvark Therapeutics Inc (AARD) is trading up at $3.90 (+4.28%), as of the latest quote. It operates in the Health Care sector.
IPO: February 13, 2025 · $16.00 offering · NASDAQ · View IPO details →
Aardvark Therapeutics Inc revenue & net income history (FY2024–FY2025)
RevenueNet income
| FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|
| Income statement | ||
| Revenue | — | $0 |
| Operating income | −$22.8M | −$62.7M |
| Net income | −$20.6M | −$57.6M |
| EPS (diluted) | −$5.15 | −$2.93 |
| Balance sheet | ||
| Cash and equivalents | $61.6M | $47.1M |
| Total assets | $77.5M | $117.2M |
| Total liabilities | $5.39M | $10.5M |
| Shareholders' equity | −$54.6M | $106.6M |
| Cash flow | ||
| Operating cash flow | −$18.1M | −$54.2M |
| Capital expenditure | $109.0K | $95.0K |
| Free cash flow | −$18.2M | −$54.3M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25†Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | $0 | — | $0 | $0 |
| Operating income | −$5.09M | −$9.45M | −$10.5M | −$15.8M | −$17.7M | — | −$22.5M | −$15.1M |
| Net income | −$4.18M | −$8.78M | −$9.31M | −$14.4M | −$16.3M | — | −$21.6M | −$14.4M |
| EPS (diluted) | −$1.05 | −$2.18 | −$0.71 | −$0.66 | −$0.75 | — | −$0.99 | −$0.66 |
| Balance sheet | ||||||||
| Cash and equivalents | $82.3M | $61.6M | $26.5M | $26.0M | $39.3M | $47.1M | $62.4M | $73.8M |
| Total assets | — | $77.5M | $157.0M | $147.5M | $133.2M | $117.2M | $98.6M | $81.5M |
| Total liabilities | — | $5.39M | $6.34M | $10.6M | $10.9M | $10.5M | $11.6M | $6.66M |
| Shareholders' equity | −$46.2M | −$54.6M | $150.7M | $136.9M | $122.4M | $106.6M | $87.0M | $74.8M |
| Cash flow | ||||||||
| Operating cash flow | −$3.96M | −$7.73M | −$11.4M | −$9.84M | −$16.1M | — | −$18.9M | −$17.6M |
| Capital expenditure | $5.00K | $6.00K | $0 | $91.0K | $4.00K | — | — | — |
| Free cash flow | −$3.96M | −$7.73M | −$11.4M | −$9.94M | −$16.1M | — | — | — |
From Aardvark Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Aardvark Therapeutics Inc
- Headquarters
- San Diego, California From SEC filings, Oct 2026
Recent News (16)
-
AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or trace…
-
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Oct. 12, 2026/PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Aardvark The…
-
-
-
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD NEW YORK, Oct. 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ: AARD) violations of the…
-
-
-
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Oct. 8, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics…
-
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Oct. 8, 2026/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Aardvark Therapeutics, Inc. (AARD) have opportunity to lead the securities fra…
-
-
-
Aardvark Therapeutics appoints David Zhang to board of directors
Aardvark Therapeutics appoints David Zhang to board of directors
-
-
-
AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky A securities class action alleges former Chief Operating Officer Bryan Jones, Ph.D. told investors in May 2025 that ARD-101 had a "very, very clean" safety profile, months before cardiac observations …
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International